MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
A phase 2 trial of Doxorubicin, Ifosfamide in vascular tumours and epithelioid sarcoma, run by HRYZ Biotech Co., now recruiting.
Overview
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma is a phase 2 interventional study registered as NCT06277154 by HRYZ Biotech Co., with 148 participants planned, started 2024-02-21 and due to reach its primary completion in 2026-02. Interventions recorded: MASCT-I, Doxorubicin, Ifosfamide. Conditions listed: Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialINT-0091 (Ewing sarcoma)
Shares Ifosfamide, Doxorubicin.
- TrialStudy of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Shares Uterine sarcoma, Doxorubicin.
- TrialTazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in)
Shares Epithelioid sarcoma, Doxorubicin.
- CancerChildhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)
Shares Ifosfamide, Rhabdomyosarcoma, Doxorubicin.
- TrialEuro Ewing 2012
Shares Ifosfamide, Doxorubicin.
- TreatmentPazopanib
Shares Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma), Uterine sarcoma.
- TrialAldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma
Shares Ifosfamide, Doxorubicin.
- TrialEURAMOS-1
Shares Ifosfamide, Doxorubicin.